News for AbCellera Biologics Inc. (ABCL)

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article.

AbCellera (ABCL) has secured a significant legal win as the United States Court of Appeals for the Federal Circuit upheld the validity of its U.S. Patent No. 10

AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of val

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermato

AbCellera (ABCL) showcases promising preclinical data for ABCL575 at the 2025 SID Annual Meeting. ABCL575 demonstrates potent inhibition

Stifel has revised its price target for AbCellera (ABCL), reducing it from $10 to $8 while maintaining a Buy rating. The adjustment comes as the company prepare

Revenue: $4 million for the quarter, down from $10 million in the same quarter of 2024.Net Loss: Approximately $46 million for the quarter, compared to a loss

Key Takeaways: AbCellera Biologics sets the stage for Phase 1 trials with financial stability ensured by substantial funding. Analysts provide a bullish

The following slide deck was published by AbCellera Biologics Inc.

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for

AbCellera (ABCL) has revealed new preclinical data on its PSMA x CD3 T-cell engagers, showcased at the American Association for Cancer Research's 116th Annual M

AbCellera (ABCL) presents promising preclinical data on its PSMA x CD3 T-cell engagers at AACR 2025. The study shows potent in vitro and in vivo anti-tu

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into […]

KeyBanc has raised its price target for AbCellera (ABCL) from $4 to $5, maintaining an Overweight rating on the stock. This adjustment comes ahead of the compan

Summary: AbCellera (ABCL) announces its Q1 2025 financial results on May 8. Analysts set a one-year average price target of $11.86, suggesting significan

AbCellera (ABCL) is actively engaging with investors through upcoming conferences to highlight its advancements in antibody medicine. Analysts suggest a

[url="]AbCellera[/url] (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at

Revenue: Approximately $29 million for the year, primarily from research fees on partnered programs, compared to $38 million in 2023.Net Loss: Roughly $163 mil